Home > Insider Trading > Filing (0000899243-19-026771)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1720725	Oyster Point Pharma Inc.	OYST	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1053891	Sacha Lainovic	126 East 56Th Street, 20Th Floor New York NY 10022	Yes	No	Yes	No
1745076	Invopps Iv Us, L.p.	126 East 56Th Street, 20Th Floor New York NY 10022	Yes	No	Yes	No
1792570	Invopps Gp Iv, L.l.c.	126 East 56Th Street, 20Th Floor New York NY 10022	Yes	No	Yes	No
1792575	Invopps Iv, L.p.	126 East 56Th Street, 20Th Floor New York NY 10022	Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.001 Per Share	Acquisiton	2019-11-04	609,965	$0.00	609,965	No	4	C	Indirect	See Footnotes
Common Stock, Par Value $0.001 Per Share	Acquisiton	2019-11-04	1,230,050	$0.00	1,230,050	No	4	C	Indirect	See Footnotes
Common Stock, Par Value $0.001 Per Share	Acquisiton	2019-11-04	248,625	$16.00	858,590	No	4	P	Indirect	See Footnotes
Common Stock, Par Value $0.001 Per Share	Acquisiton	2019-11-04	501,375	$16.00	1,731,425	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock, Par Value $0.001 Per Share	Series B Convertible Preferred Stock	Disposition	2019-11-04	609,965	$0.00	609,965	$0.00
Common Stock, Par Value $0.001 Per Share	Series B Convertible Preferred Stock	Disposition	2019-11-04	1,230,050	$0.00	1,230,050	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

These shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock (the "Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series B Convertible Preferred Stock had no expiration date.
Reflects securities directly held by InvOpps IV US, L.P. ("Invus IV US").
Reflects securities directly held by InvOpps IV, L.P. ("Invus IV").
InvOpps GP IV, L.L.C. ("InvOpps GP") is the sole general partner of each of Invus IV and Invus IV US. Sacha Lainovic is the managing member of InvOpps GP.
Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.